Selected research
Industry Research
Corticosteroids Inhalation Formulation Industry Research Report 2026
Market perspective
The global Corticosteroids Inhalation Formulation market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Corticosteroids Inhalation Formulation is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Corticosteroids Inhalation Formulation is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Corticosteroids Inhalation Formulation is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Corticosteroids Inhalation Formulation include Novartis, Merck, GSK, AstraZeneca, Viatris, Teva Respiratory, Recipharm AB, Perrigo and Organon Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Corticosteroids Inhalation Formulation market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Corticosteroids Inhalation Formulation Market by Company
Novartis
Merck
GSK
AstraZeneca
Viatris
Teva Respiratory
Recipharm AB
Perrigo
Organon Group
Lupin
Cipla
Boehringer Ingelheim International
Corticosteroids Inhalation Formulation Segment by Type
Beclomethasone
Budesonide
Fluticasone
Mometasone Furoate
Other
Corticosteroids Inhalation Formulation Segment by Application
Specialty Clinics
Hospitals
Online Pharmacies
Retail Pharmacy Chains
Other
Corticosteroids Inhalation Formulation Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Corticosteroids Inhalation Formulation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Corticosteroids Inhalation Formulation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Corticosteroids Inhalation Formulation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Corticosteroids Inhalation Formulation manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Corticosteroids Inhalation Formulation by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Corticosteroids Inhalation Formulation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Beclomethasone
- Budesonide
- Fluticasone
- Mometasone Furoate
- Other
Applications
- Specialty Clinics
- Hospitals
- Online Pharmacies
- Retail Pharmacy Chains
- Other
Companies covered
- Novartis
- Merck
- GSK
- AstraZeneca
- Viatris
- Teva Respiratory
- Recipharm AB
- Perrigo
- Organon Group
- Lupin
- Cipla
- Boehringer Ingelheim International
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Corticosteroids Inhalation Formulation Market Size (2021-2032)
- 2.2.2 Global Corticosteroids Inhalation Formulation Sales (2021-2032)
- 2.2.3 Global Corticosteroids Inhalation Formulation Market Average Price (2021-2032)
- 2.3 Corticosteroids Inhalation Formulation by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Beclomethasone
- 2.3.3 Budesonide
- 2.3.4 Fluticasone
- 2.3.5 Mometasone Furoate
- 2.3.6 Other
- 2.4 Corticosteroids Inhalation Formulation by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Specialty Clinics
- 2.4.3 Hospitals
- 2.4.4 Online Pharmacies
- 2.4.5 Retail Pharmacy Chains
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Corticosteroids Inhalation Formulation Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Corticosteroids Inhalation Formulation Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Corticosteroids Inhalation Formulation Revenue of Manufacturers (2021-2026)
- 3.4 Global Corticosteroids Inhalation Formulation Average Price by Manufacturers (2021-2026)
- 3.5 Global Corticosteroids Inhalation Formulation Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Corticosteroids Inhalation Formulation, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Corticosteroids Inhalation Formulation, Product Type & Application
- 3.8 Global Manufacturers of Corticosteroids Inhalation Formulation, Established Date
- 3.9 Global Corticosteroids Inhalation Formulation Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Corticosteroids Inhalation Formulation Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Corticosteroids Inhalation Formulation Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 GSK
- 4.3.1 GSK Company Information
- 4.3.2 GSK Business Overview
- 4.3.3 GSK Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GSK Corticosteroids Inhalation Formulation Product Portfolio
- 4.3.5 GSK Recent Developments
- 4.4 AstraZeneca
- 4.4.1 AstraZeneca Company Information
- 4.4.2 AstraZeneca Business Overview
- 4.4.3 AstraZeneca Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AstraZeneca Corticosteroids Inhalation Formulation Product Portfolio
- 4.4.5 AstraZeneca Recent Developments
- 4.5 Viatris
- 4.5.1 Viatris Company Information
- 4.5.2 Viatris Business Overview
- 4.5.3 Viatris Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Viatris Corticosteroids Inhalation Formulation Product Portfolio
- 4.5.5 Viatris Recent Developments
- 4.6 Teva Respiratory
- 4.6.1 Teva Respiratory Company Information
- 4.6.2 Teva Respiratory Business Overview
- 4.6.3 Teva Respiratory Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Teva Respiratory Corticosteroids Inhalation Formulation Product Portfolio
- 4.6.5 Teva Respiratory Recent Developments
- 4.7 Recipharm AB
- 4.7.1 Recipharm AB Company Information
- 4.7.2 Recipharm AB Business Overview
- 4.7.3 Recipharm AB Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Recipharm AB Corticosteroids Inhalation Formulation Product Portfolio
- 4.7.5 Recipharm AB Recent Developments
- 4.8 Perrigo
- 4.8.1 Perrigo Company Information
- 4.8.2 Perrigo Business Overview
- 4.8.3 Perrigo Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Perrigo Corticosteroids Inhalation Formulation Product Portfolio
- 4.8.5 Perrigo Recent Developments
- 4.9 Organon Group
- 4.9.1 Organon Group Company Information
- 4.9.2 Organon Group Business Overview
- 4.9.3 Organon Group Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Organon Group Corticosteroids Inhalation Formulation Product Portfolio
- 4.9.5 Organon Group Recent Developments
- 4.10 Lupin
- 4.10.1 Lupin Company Information
- 4.10.2 Lupin Business Overview
- 4.10.3 Lupin Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Lupin Corticosteroids Inhalation Formulation Product Portfolio
- 4.10.5 Lupin Recent Developments
- 4.11 Cipla
- 4.11.1 Cipla Company Information
- 4.11.2 Cipla Business Overview
- 4.11.3 Cipla Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cipla Corticosteroids Inhalation Formulation Product Portfolio
- 4.11.5 Cipla Recent Developments
- 4.12 Boehringer Ingelheim International
- 4.12.1 Boehringer Ingelheim International Company Information
- 4.12.2 Boehringer Ingelheim International Business Overview
- 4.12.3 Boehringer Ingelheim International Corticosteroids Inhalation Formulation Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Boehringer Ingelheim International Corticosteroids Inhalation Formulation Product Portfolio
- 4.12.5 Boehringer Ingelheim International Recent Developments
5 Global Corticosteroids Inhalation Formulation Market Scenario by Region
- 5.1 Global Corticosteroids Inhalation Formulation Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Corticosteroids Inhalation Formulation Sales by Region: 2021-2032
- 5.2.1 Global Corticosteroids Inhalation Formulation Sales by Region: 2021-2026
- 5.2.2 Global Corticosteroids Inhalation Formulation Sales by Region: 2027-2032
- 5.3 Global Corticosteroids Inhalation Formulation Revenue by Region: 2021-2032
- 5.3.1 Global Corticosteroids Inhalation Formulation Revenue by Region: 2021-2026
- 5.3.2 Global Corticosteroids Inhalation Formulation Revenue by Region: 2027-2032
- 5.4 North America Corticosteroids Inhalation Formulation Market Facts & Figures by Country
- 5.4.1 North America Corticosteroids Inhalation Formulation Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
- 5.4.3 North America Corticosteroids Inhalation Formulation Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Corticosteroids Inhalation Formulation Market Facts & Figures by Country
- 5.5.1 Europe Corticosteroids Inhalation Formulation Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
- 5.5.3 Europe Corticosteroids Inhalation Formulation Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Corticosteroids Inhalation Formulation Market Facts & Figures by Country
- 5.6.1 Asia Pacific Corticosteroids Inhalation Formulation Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Corticosteroids Inhalation Formulation Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Corticosteroids Inhalation Formulation Market Facts & Figures by Country
- 5.7.1 South America Corticosteroids Inhalation Formulation Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
- 5.7.3 South America Corticosteroids Inhalation Formulation Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Corticosteroids Inhalation Formulation Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Corticosteroids Inhalation Formulation Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Corticosteroids Inhalation Formulation Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Corticosteroids Inhalation Formulation Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Corticosteroids Inhalation Formulation Sales by Type (2021-2032)
- 6.1.1 Global Corticosteroids Inhalation Formulation Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Corticosteroids Inhalation Formulation Sales Market Share by Type (2021-2032)
- 6.2 Global Corticosteroids Inhalation Formulation Revenue by Type (2021-2032)
- 6.2.1 Global Corticosteroids Inhalation Formulation Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Corticosteroids Inhalation Formulation Revenue Market Share by Type (2021-2032)
- 6.3 Global Corticosteroids Inhalation Formulation Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Corticosteroids Inhalation Formulation Sales by Application (2021-2032)
- 7.1.1 Global Corticosteroids Inhalation Formulation Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Corticosteroids Inhalation Formulation Sales Market Share by Application (2021-2032)
- 7.2 Global Corticosteroids Inhalation Formulation Revenue by Application (2021-2032)
- 7.2.1 Global Corticosteroids Inhalation Formulation Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Corticosteroids Inhalation Formulation Revenue Market Share by Application (2021-2032)
- 7.3 Global Corticosteroids Inhalation Formulation Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Corticosteroids Inhalation Formulation Value Chain Analysis
- 8.1.1 Corticosteroids Inhalation Formulation Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Corticosteroids Inhalation Formulation Production Mode & Process
- 8.2 Corticosteroids Inhalation Formulation Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Corticosteroids Inhalation Formulation Distributors
- 8.2.3 Corticosteroids Inhalation Formulation Customers
9 Global Corticosteroids Inhalation Formulation Analyzing Market Dynamics
- 9.1 Corticosteroids Inhalation Formulation Industry Trends
- 9.2 Corticosteroids Inhalation Formulation Industry Drivers
- 9.3 Corticosteroids Inhalation Formulation Industry Opportunities and Challenges
- 9.4 Corticosteroids Inhalation Formulation Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst